To find conserved gene targets of the CEBPA-TET2 axis, we integrated the transcriptomic data from our in vitro and in vivo models with gene expression analyses from AML patients harboring CEBPA and TET2 mutations. This evidence concerns the gene TET2 and acute myeloid leukemia.